AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Littauer, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Littauer, P.
Antimicrobial Agents and Chemotherapy, May 2006, p. 1896-1899, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1896-1899.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Macrolide-Resistant Streptococcus pyogenes in Norway: Population Structure and Resistance Determinants

P. Littauer,1* D. A. Caugant,2,3 M. Sangvik,1 E. A. Høiby,2 A. Sundsfjord,1,2 G. S. Simonsen,1,2 and the Norwegian Macrolide Study Group{dagger}

Department of Microbiology and Infection Control, University Hospital of North Norway, and Department of Microbiology and Virology, Institute of Medical Biology, Faculty of Medicine, University of Tromsø, Tromsø,1 Division of Infectious Disease Control, Norwegian Institute of Public Health,2 Institute of Oral Biology, University of Oslo, Oslo, Norway3

Received 20 November 2005/ Returned for modification 9 January 2006/ Accepted 17 February 2006

A 2.7% prevalence of macrolide resistance in 1,657 Norwegian clinical Streptococcus pyogenes isolates was primarily due to erm(TR) (59%) and mef(A) (20%). Four clonal complexes comprised 75% of the strains. Macrolide resistance in S. pyogenes in Norway is imported as resistant strains or locally selected in internationally disseminated susceptible clones.

* Corresponding author. Mailing address: Department of Microbiology and Infection Control, University Hospital of North Norway and Department of Microbiology and Virology, Faculty of Medicine, Institute for Medical Biology, University of Tromsø, N-9037 Tromsø, Norway. Phone: 47 77 66 96 32. Fax: 47 77 62 70 15. E-mail: Pia.Littauer{at}unn.no.

{dagger} Members of the Norwegian Macrolide Study Group are listed in the acknowledgments.

Antimicrobial Agents and Chemotherapy, May 2006, p. 1896-1899, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1896-1899.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.